Reviewed By:
Robin Schoenthaler, MD (Oncology)
Board certified radiation oncologist with over 30 years experience treating cancer patients. Senior physician advisor for expert medical options in adult oncology. Published award-winning essayist on medical and health issues and more.
Aiko Yoshioka, MD (Gastroenterology)
Dr. Yoshioka graduated from the Niigata University School of Medicine. He worked as a gastroenterologist at Saiseikai Niigata Hospital and Niigata University Medical & Dental Hospital before serving as the Deputy Chief of Gastroenterology at Tsubame Rosai Hospital and Nagaoka Red Cross Hospital. Dr. Yoshioka joined Saitama Saiseikai Kawaguchi General Hospital as Chief of Gastroenterology in April 2018.
Content updated on Jan 19, 2024
Following the Medical Content Editorial Policy
Worried about your symptoms?
Choose one to start our AI Symptom Checker.
It will help us optimize further questions for you.
By starting the symptom checker, you agree to the Privacy Policy and Terms of Use
Fatigued
Yellow eyes
Upper right abdominal pain
Loss of appetite
Stomachache
Itchy
Unintentional weight loss of more than 5% in one month
Not seeing your symptoms? No worries!
With an easy 3-min questionnaire , Ubie's AI-powered system will generate a free report on possible causes.
Questions are customized to your situation and symptoms, including the following personal information:
Biological Sex - helps us provide relevant suggestions for male vs. female conditions.
Age - adjusts our guidance based on any age-related health factors.
History - considers past illnesses, surgeries, family history, and lifestyle choices.
Your symptoms
Our AI
Your report
Your personal report will tell you
✔ When to see a doctor
✔︎ What causes your symptoms
✔︎ Treatment information etc.
See full list
Cancer of the bile ducts is also known as "cholangiocarcinoma." It is a cancer that arises in the bile ducts inside the liver or in the ducts that connect the liver to the gall bladder and intestines. Risk factors include genetic conditions, a condition called primary sclerosing cholangitis, chronic liver disease, infection with liver worms (flukes), smoking, diabetes, and age >50. Patients often come to their physicians with abdominal pain, jaundice (yellow skin and eyeballs), itchiness, and weight loss.
Your doctor may ask these questions to check for this disease:
This cancer is treated by a team of of oncologists including surgeons, medical oncologists and radiation oncologists. A biopsy is usually performed to confirm the diagnosis. The treatment choices depend on stage, location, and other factors which are revealed by ultrasounds, CT scans, special scans and procedures, and MRIs. Treatments may include chemotherapy, immunotherapy, and various kinds of radiation therapy. Surgery is used less often. If larger bile ducts are blocked by tumor, temporary or permanent stents (tubes) may be inserted to bypass the blockage.
Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021 Jan 30;397(10272):428-444. doi: 10.1016/S0140-6736(21)00153-7. PMID: 33516341.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00153-7/fulltextBridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary Tract Cancer: Epidemiology, Radiotherapy, and Molecular Profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194-203. doi: 10.1200/EDBK_160831. PMID: 27249723.
https://ascopubs.org/doi/10.1200/EDBK_160831Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021 May;15(5):527-536. doi: 10.1080/17474124.2021.1853527. Epub 2021 Jan 8. PMID: 33215952.
https://www.tandfonline.com/doi/full/10.1080/17474124.2021.1853527Nara S, Esaki M, Ban D, Takamoto T, Shimada K, Ioka T, Okusaka T, Ishii H, Furuse J. Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials. Jpn J Clin Oncol. 2020 Dec 16;50(12):1353-1363. doi: 10.1093/jjco/hyaa170. PMID: 33037430.
https://academic.oup.com/jjco/article/50/12/1353/5919787Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer. J Hepatol. 2020 Jul;73(1):170-185. doi: 10.1016/j.jhep.2020.03.007. Epub 2020 Mar 12. PMID: 32171892.
https://www.journal-of-hepatology.eu/article/S0168-8278(20)30165-3/fulltextMale, 30s
I got more answers in one minute through your site than I did in three hours with Google.
(Sep 29, 2024)
Male, 20s
My experience was great. I was worried, but the symptom checker helped me narrow down what it might be. I feel a little relieved compared to when I first started, and it gives me a starting point for what my symptoms could mean.
(Sep 27, 2024)
Male, 50s
The questions asked and possible causes seemed spot on, putting me at ease for a next-step solution.
(Sep 26, 2024)
Female, 40s
I was actually very impressed with the results it provided because, although I didn’t mention it during the questionnaire because I thought it was unrelated, it suggested I may have something I’ve actually been diagnosed with in the past.
(Sep 25, 2024)
Reviewed By:
Robin Schoenthaler, MD (Oncology)
Board certified radiation oncologist with over 30 years experience treating cancer patients. Senior physician advisor for expert medical options in adult oncology. Published award-winning essayist on medical and health issues and more.
Aiko Yoshioka, MD (Gastroenterology)
Dr. Yoshioka graduated from the Niigata University School of Medicine. He worked as a gastroenterologist at Saiseikai Niigata Hospital and Niigata University Medical & Dental Hospital before serving as the Deputy Chief of Gastroenterology at Tsubame Rosai Hospital and Nagaoka Red Cross Hospital. Dr. Yoshioka joined Saitama Saiseikai Kawaguchi General Hospital as Chief of Gastroenterology in April 2018.
Our symptom checker AI is continuously refined with input from experienced physicians, empowering them to make more accurate diagnoses.
“World’s Best Digital
Health Companies”
Newsweek 2024
“Best With AI”
Google Play Best of 2023
“Best in Class”
Digital Health Awards 2023 (Quarterfinalist)
Ubie’s symptom checker demonstrated a Top-10 hit accuracy of 71.6%, surpassing the performance of several leading symptom checkers in the market, which averaged around 60% accuracy in similar assessments.
Link to full study:
https://www.medrxiv.org/content/10.1101/2024.08.29.24312810v1